Software development for quantitative analysis of brain amyloid PET

Hiroshi Matsuda1,2,3 | Tensho Yamao2,4

1 Department of Biofunctional Imaging, Fukushima Medical University, Fukushima City, Fukushima, Japan
2 Drug Discovery and Cyclotron Research Center, Southern Tohoku Research Institute for Neuroscience, Koriyama, Fukushima, Japan
3 Department of Radiology, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan
4 Department of Radiological Sciences, School of Health Sciences, Fukushima Medical University, Sakae, Fukushima, Japan

Correspondence
Hiroshi Matsuda, Department of Biofunctional Imaging, Fukushima Medical University, 6F(621), Shin-OTemachi Building, 2-2-1, Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan.
Email: matsudah@ncnp.go.jp

Abstract

Introduction: Centiloid (CL) scaling has become a standard quantitative measure in amyloid PET because it allows the direct comparison of results across sites, even when different analytical methods or PET tracers are used.

Methods: In the present study, we developed new standalone software to easily handle a pipeline for accurate calculation of the CL scale for the five currently available amyloid PET tracers—11C-PiB, 18F-florbetapir, 18F-flutemetamol, 18F-florbetaben, and 18F-NAV4694. This pipeline requires reorientation and coregistration of PET and MRI, anatomic standardization of coregistered PET to a standardized space using a warping parameter for coregistered MRI, application of standard volumes of interest (VOIs) to the warped PET, calculation of the standardized uptake value ratio (SUVR) for the target VOIs, and finally conversion of the SUVR to the CL scale. The PET data for these tracers were collected from the publicly available Global Alzheimer’s Association Interactive Network (GAIN) repository. We also developed software to map Z-scores for the statistical comparison of a patient’s PET data with a negative control database obtained from young healthy controls in the GAIN repository.

Results: When whole cerebellum or whole cerebellum plus brainstem was chosen as the reference area, an excellent correlation was found between the CL scale calculated by this software and the CL scale published by GAIN. There were no significant differences in the detection performance of significant amyloid accumulation using Z-score mapping between each 18F-labeled tracer and 11C-PiB. The cutoff CL values providing the most accurate detection of regional amyloid positivity in Z-score mapping were 11.8, 14.4, 14.7, 15.6, and 17.7 in the posterior cingulate gyrus and precuneus, frontal cortex, temporal cortex, parietal cortex, and striatum, respectively.

Conclusion: This software is able to not only provide reliable calculation of the global CL scale but also detect significant local amyloid accumulation in an individual patient.

KEYWORDS
amyloid, brain, Centiloid scale, PET, quantification

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC
1 | INTRODUCTION

Amyloid positron emission tomography (PET) increases the diagnostic accuracy of Alzheimer’s disease (AD) and non-AD. Because the binary classification of positive and negative amyloid PET findings is routinely based on visual interpretation, equivocation is inevitable and leads to interrater variability (Hosokawa et al., 2015). Equivocal findings should be avoided when the indication is being determined for the disease-modifying drugs currently under development. Accordingly, quantitative analysis has been proposed as an aid to visual interpretation (Collij et al., 2019; Matsuda et al., 2021).

The standardized uptake value ratio (SUVR) has been widely applied to the quantitative analysis of amyloid PET. However, SUVR values depend not only on the target and reference regions used, but also on the particular amyloid PET tracer. This variability can be resolved through a Centiloid (CL) scaling process that standardizes the quantitative amyloid imaging measures by standardizing the outcome of each analytical method or PET ligand to a scale from 0 to 100 (Klunk et al., 2015). The CL scale offers a direct comparison of results across institutions, even when different analytical methods or tracers are used, and may enable the clear definition of cut-offs for amyloid positivity. To determine the CL scale, it is necessary to follow the method put forward by the Global Alzheimer’s Association Interactive Network (GAAIN, http://www.gaain.org/centiloid-project). However, this approach is time-consuming because it requires numerous steps to process the PET images and the corresponding MRI data and the use of multiple software packages. Furthermore, to more reliably determine amyloid positivity, the local pattern of amyloid accumulation should be captured, in addition to the global CL scale. To resolve these issues, we have developed standalone software for both calculating the global CL scale and detecting which brain regions have statistically significant amyloid accumulation. In the present study, we describe the details of this new software and its validation.

2 | MATERIALS AND METHODS

2.1 | Data availability

This study was conducted using datasets collected from the publicly available GAAIN repository. These datasets comprised 495 PET images obtained using five different amyloid PET tracers (\[\text{\textsuperscript{11}C-PiB}, \text{\textsuperscript{18}F-florbetapir}, \text{\textsuperscript{18}F-flutemetamol}, \text{\textsuperscript{18}F-florbetaben}, \text{\textsuperscript{18}F-NAV4694}\]) and the corresponding three-dimensional T1-weighted MRI data of patients with AD, frontotemporal dementia, and mild cognitive impairment and of young and elderly healthy controls (Table 1). Acquisition of PET scan images were done from 50 to 70 min for \text{\textsuperscript{11}C-PiB} and \text{\textsuperscript{18}F-NAV4694}, from 50 to 60 min for \text{\textsuperscript{18}F-florbetapir}, and 90 to 110 min for \text{\textsuperscript{18}F-flutemetamol} and \text{\textsuperscript{18}F-florbetaben} after administration of the PET tracer.

2.2 | Processing pipeline of the software

The software developed in this study comprises two distinct processes: calculation of the CL scale from each subject’s amyloid PET and MRI, and a statistical comparison of each subject’s amyloid PET with a database of negative amyloid PET results obtained from young healthy controls.

The first process for quantitative analysis using the SUVR and a 100-point scale termed the CL scale is illustrated in Figure 1. First, a pair of subject PET and subject MRI images is input in DICOM or NIfTI format. Then, the subject MRI was reoriented by setting the origin around the anterior commissure and coregistered to the Montreal Neurological Institute (MNI) template (avg152T1.nii). The subject PET was then reoriented also by setting the origin around the anterior commissure and coregistered to the coregistered subject MRI. Then, the coregistered subject MRI was warped into MNI space using unified segmentation (Ashburner & Friston, 2005). The parameters of the deformation field in this warping are applied to the coregistered subject PET images.

### Table 1

| PET tracer          | MRI            | Subjects | Total number | Patients (age) | EHC (age) | YHC (age) |
|---------------------|----------------|----------|--------------|----------------|-----------|-----------|
| \[\text{\textsuperscript{11}C-PiB}\] | 3D T1WI       | 79       | 45 AD (N/A)  | 0 (N/A)        | 34 (N/A)  |
| \[\text{\textsuperscript{18}F-florbetapir} + \text{\textsuperscript{11}C-PiB}\] | 3D T1WI       | 46       | 17 AD (51–76 yo), 7 MCI (64–89 yo), 3 At risk elderly (78–83 yo) | 6 (51–75 yo) | 13 (21–35 yo) |
| \[\text{\textsuperscript{18}F-flutemetamol} + \text{\textsuperscript{11}C-PiB}\] | 3D T1WI       | 73       | 20 AD (60–81 yo), 20 MCI (57–83 yo) | 9 (47–75 yo) | 24 (31–45 yo) |
| \[\text{\textsuperscript{18}F-florbetaben} + \text{\textsuperscript{11}C-PiB}\] | 3D T1WI       | 35       | 8 AD (61–77 yo), 9 MCI (65–80 yo), 2 FTD (68–79 yo) | 6 (63–84 yo) | 10 (25–46 yo) |
| \[\text{\textsuperscript{18}F-NAV4694} + \text{\textsuperscript{11}C-PiB}\] | 3D T1WI       | 54       | 7 AD (59–83 yo), 9 MCI (60–89 yo), 3 FTD (63–72 yo) | 25 (57–89 yo) | 10 (26–45 yo) |

AD, Alzheimer’s disease; MCI, mild cognitive impairment; FTD, frontotemporal dementia; EHC, elderly healthy control; YHC, young healthy control; 3D T1WI, three-dimensional T1-weighted image; N/A, not available; yo, years old.
FIGURE 1  Processing pipeline for quantitative measurements of amyloid accumulation in the target area of the cerebral cortex and striatum. The subject MRI was reoriented by setting the origin around the anterior commissure and coregistered to the Montreal Neurological Institute (MNI) template (avg152T1.nii). The subject PET was then reoriented also by setting the origin around the anterior commissure and coregistered to the coregistered subject MRI. Then, the coregistered subject MRI was warped into MNI space using unified segmentation. The parameters of the deformation field in this warping are applied to the coregistered subject PET images for anatomic standardization into MNI space. These translations were performed using the Statistical Parametric Mapping (SPM) 12 software. The SUVR is calculated from the amyloid PET counts in the cerebral cortical and striatal (ctx) volumes of interest (VOIs) and in a reference VOI using Global Alzheimer’s Association Initiative Network (GAAIN) standard VOI templates. Next, the SUVR is converted to CL values using direct conversion equations (Table 2) for each PET tracer, as described in previous reports (Battle et al., 2018; Klunk et al., 2015; Navitsky et al., 2018; Rowe et al., 2016; Rowe et al., 2017).

The second process, which involves comparison of each subject’s PET data with a negative normal database comprising young healthy controls, is illustrated in Figure 3. First, the standardized subject PET images are smoothed using an 8-mm³ Gaussian kernel. The smoothed and standardized subject PET images are then masked to remove white matter areas with high counts after normalization of the PET count using a reference volume of interest (VOI) count. Masked mean

for anatomic standardization into MNI space. These translations were performed using the Statistical Parametric Mapping (SPM) 12 software (https://www.fil.ion.ucl.ac.uk/spm). The SUVR is calculated from standardized subject PET counts in four reference regions—the whole cerebellum (GAAIN WhlCbl VOI), cerebellar gray matter (GAAIN CerebGry VOI), pons (GAAIN Pons VOI), and whole cerebellum plus brainstem (GAAIN WhlCblBrnStm VOI) (Figure 2a)—and in the global cortical target region (GAAIN ctx VOI) (Figure 2b). Finally, the SUVR is converted to CL values using direct conversion equations (Table 2) for each PET tracer, as described in previous reports (Battle et al., 2018; Klunk et al., 2015; Navitsky et al., 2018; Rowe et al., 2016; Rowe et al., 2017).
and standard deviation PET images are generated from an amyloid-negative control database comprising smoothed and standardized subject PET images of young healthy controls with a CL score less than 10 published on the GAAIN website for each PET tracer (34 subjects for $^{11}$C-PiB, 10 for $^{18}$F-florbetapir, 23 for $^{18}$F-flutemetamol, 10 for $^{18}$F-florbetaben, and 10 for $^{18}$F-NAV4694). A CL score less than 10 has been reported to be optimal for excluding neuritic plaques in comparisons of amyloid PET measures with neuropathological findings (Amadoru et al., 2020). A Z-score map for masked, smoothed, and standardized subject PET data is displayed by overlay on tomographic sections with a contour of the target cortical and striatal areas and with surface rendering (Figure 4) of the standardized brain MRI data using the following equation: $Z$-score = ([individual count] − [mean count of control database])/(standard deviation count of control database). In
FIGURE 3  Processing pipeline for comparison of each subject’s PET data with a negative normal database comprising young healthy controls. The standardized subject PET is smoothed using an 8-mm³ Gaussian kernel. The smoothed and standardized subject PET images are then masked to remove white matter areas with high counts after normalization of the PET count using the reference VOI count. A Z-score is calculated from a comparison of masked, smoothed, and standardized subject PET images with masked mean and standard deviation PET images generated from an amyloid-negative control database comprising smoothed and standardized subject PET images of young healthy controls from the GAAIN dataset repository. A Z-score map is displayed by overlay on tomographic sections with a contour of the target cortical and striatal area and surface rendering of the standardized brain MRI.

2.3  Validation of the software for CL calculation

The CL scales calculated using the present software were compared with the CL scales published on the GAAIN website for each PET tracer and each reference VOI. For validation, as defined by Klunk et al. (2015), the slope should be between 0.98 and 1.02 and the intercept between −2 and +2 CL for a linear regression equation and the $R^2$ correlation coefficient should exceed 0.98.
2.4 Evaluation of Z-score mapping

To evaluate the regional detectability of significant amyloid accumulation using each $^{18}$F-labeled tracer, we compared the presence or absence of areas with significant amyloid accumulation in five regions (the posterior cingulate cortex and precuneus, frontal cortex, temporal cortex, parietal cortex, and striatum; Figure 2c) of the target cortical areas between each $^{18}$F-labeled tracer and the corresponding $^{11}$C-PiB PET images from the same individuals ($\chi^2$ test). To avoid false positives, we set a Z-score threshold of 2.6 corresponding to $p < 0.01$ with sufficiently large cluster size of 300 voxels (2.4 cc). We then performed receiver operating characteristic (ROC) analysis on the pooled data of all PET tracers to evaluate the relationship between the global CL scale and the positive or negative findings for regional amyloid accumulation.
TABLE 3  Correlation coefficient and linear regression equation between the CL scales calculated by the present software and those published on the GAAIN website

| Amyloid PET tracer | Number of subjects | R²  | Slope | Intercept | R²  | Slope | Intercept | R²  | Slope | Intercept | R²  | Slope | Intercept |
|--------------------|--------------------|-----|-------|----------|-----|-------|----------|-----|-------|----------|-----|-------|----------|
| ¹¹C-PiB            | 287                | 0.993 | 1.01 | 0.64     | 0.993 | 1.01 | 1.36     | 0.996 | 1.00 | 0.27     | 0.996 | 0.98 | −1.64    |
| ¹⁸F-florbetapir     | 46                 | 0.991 | 1.00 | 0.1      | N/A | N/A  | N/A      | N/A | N/A  | N/A      | N/A | N/A  | N/A      |
| ¹⁸F-flutemetamol    | 73                 | 0.982 | 1.01 | 0.27     | N/A | N/A  | N/A      | N/A | N/A  | N/A      | N/A | N/A  | N/A      |
| ¹⁸F-florbetaben     | 35                 | 0.997 | 0.99 | 0.97     | 0.994 | 0.98 | 2.6      | 0.997 | 0.99 | 0.17     | 0.942 | 0.94 | 1.5      |
| ¹⁸F-NAV4694         | 54                 | 0.998 | 0.99 | 0.02     | 0.997 | 1.00 | 0.6      | 0.998 | 0.99 | −0.29    | 0.997 | 0.97 | −1.67    |

VOI, volume of interest; WhlCbl, whole cerebellum; CerebGry, cerebellar gray matter; WhlCblBrnStm, whole cerebellum plus brain stem; N/A, not available.

3 | RESULTS

When the whole cerebellum or whole cerebellum plus brainstem was chosen as the reference VOI, an excellent correlation between the CL scales calculated by this software and those published on the GAAIN website was confirmed by the fact that the correlation coefficient, as well as the slope and intercept of the linear regression equation, were within the range allowed by Klunk et al. (2015) in each of the four chosen reference regions using the five different PET tracers (Table 3). When cerebellar gray matter was chosen as the reference VOI, the intercept for ¹⁸F-florbetaben exceeded the allowed range. When the pons was chosen as the reference VOI, the slope for ¹⁸F-florbetaben and ¹⁸F-NAV4694 and the correlation coefficient for ¹⁸F-florbetaben exceeded the allowed ranges.

A comparison of the detection performance of significant amyloid accumulation in the five regions using Z-score mapping revealed no statistically significant difference (p > 0.3) between each ¹⁸F-labeled tracer and the corresponding ¹¹C-PiB in the same individuals (Table 4). In the 495 amyloid PET studies, ROC analysis between Z-score mapping and the global CL scale showed that the CL scale could determine the positivity of local amyloid accumulation with high accuracy (Table 5). The cutoff CL values for amyloid positivity were 11.8, 14.4, 14.7, 15.6, and 17.7 in the posterior cingulate gyrus and precuneus, frontal cortex, temporal cortex, parietal cortex, and striatum, respectively.

4 | DISCUSSION

In the present study, we developed standalone software for quantifying amyloid PET. This software provides both the global level of amyloid accumulation in the cerebral cortex and striatum as CL values and a Z-score map displaying local amyloid accumulation with statistical significance versus a negative database generated from young controls. The accuracy of the CL values calculated using the present software was validated by comparison with the values published on the GAAIN website. Z-score mapping was able to elucidate the exact location of significant increase of amyloid accumulation. As the CL score increased, the local amyloid accumulation became significant in the order of the posterior cingulate gyrus and precuneus, frontal cortex, temporal cortex, parietal cortex, and striatum.

Selection of the whole cerebellum or whole cerebellum plus brainstem as the reference area revealed an excellent correlation between the CL values calculated by the present software and those published on the GAAIN website, irrespective of the PET tracers used. On the other hand, selection of the cerebellar gray matter resulted in a worse correlation in ¹⁸F-labeled tracers, and selection of the pons resulted in the worst correlation. These results are compatible with those of a previous report by Klunk et al. (2015). They reported the SUV ratio values of ¹¹C-PiB PET in AD patients and young healthy controls using the same standard reference regions after anatomic standardization of PET images using the same manner as in the present study. They demonstrated smaller variance in the SUV ratio in each group and a larger effect size with the whole cerebellum or whole cerebellum plus brainstem than with the cerebellar gray matter or pons. The pons had the largest variance and smallest effect size. They speculated that this poor performance with cerebellar gray matter may result from difficulty in removing the adjacent cerebellar white matter with high accumulation and that the worst performance with the pons may result from less accurate anatomic standardization in SPM for brainstem structures compared with cortical structures.

Z-score analysis to compare the subject’s PET data with a negative database of young controls demonstrated equivalent sensitivity of statistically significant regional amyloid accumulation between each ¹⁸F-labeled tracer and ¹¹C-PiB. In this cross-sectional study, using the global CL scale as an indicator of AD progression, amyloid accumulation began in the posterior cingulate gyrus and precuneus and spread to the frontal cortex, lateral temporal cortex, and parietal cortex and finally to the striatum. Furthermore, the global CL scale can be used to estimate the graded positivity of local amyloid accumulation with high accuracy. Several spatial and temporal orderings of amyloid positivity using PET have been reported, and the results are similar to
TABLE 4  Comparison of negative or positive findings in target regions using Z-score mapping between 18F-labeled tracer and 11C-PiB

| Combination of amyloid PET tracers | Target region | Posterior cingulate gyrus/precuneus | Frontal cortex | Temporal cortex | Parietal cortex | Striatum |
|-----------------------------------|---------------|------------------------------------|----------------|----------------|---------------|---------|
|                                   |               | Negative   | Positive   | Negative   | Positive   | Negative   | Positive   | Negative   | Positive   | Negative   | Positive   | Negative   | Positive   |
| 18F-florbetapir                   | 11C-PiB       | 20         | 26         | 23          | 23          | 24          | 22          | 24          | 22          | 27          | 19        |
| $\chi^2$                          | 0.393         | 0.044      | 0          | 0.044      | 0.177       | 0.044      | 0.177       | 0.044      | 0.177       | 0.044      | 0.177     |
| p Value                           | 0.531         | 0.835      | 1          | 0.835      | 0.674       | 0.835      | 0.674       | 0.835      | 0.674       | 0.835      | 0.674     |
| 18F-flutemetamol                  | 11C-PiB       | 43         | 30         | 42          | 31          | 43          | 30          | 43          | 30          | 43          | 30        |
| $\chi^2$                          | 0.028         | 0.028      | 0          | 0          | 0.057       | 0          | 0.057       | 0          | 0.057       | 0          | 0.057     |
| p Value                           | 0.867         | 0.867      | 1          | 1          | 1           | 1          | 1           | 1          | 1           | 1          | 1         |
| 18F-florbetaben                   | 11C-PiB       | 15         | 20         | 13          | 22          | 17          | 18          | 18          | 17          | 18          | 17        |
| $\chi^2$                          | 0.543         | 0.238      | 0.238      | 0.238      | 0.057       | 0          | 0.057       | 0          | 0.057       | 0          | 0.057     |
| p Value                           | 0.461         | 0.625      | 0.625      | 0.625      | 1           | 0          | 1           | 0          | 1           | 0          | 1         |
| 18F-NAV4694                       | 11C-PiB       | 29         | 25         | 36          | 18          | 35          | 19          | 36          | 18          | 39          | 15        |
| $\chi^2$                          | 0.607         | 0.162      | 0.167      | 0.167      | 0.172       | 0          | 0.172       | 0          | 0.172       | 0          | 0.172     |
| p Value                           | 0.436         | 0.687      | 0.683      | 0.683      | 0.678       | 1          | 0.678       | 1          | 0.678       | 1          | 0.678     |

TABLE 5  ROC analysis between regional positivity using Z-score mapping and the global CL scale for the pooled data of all PET tracers

| Target region | Posterior cingulate gyrus/precuneus | Frontal cortex | Temporal cortex | Parietal cortex | Striatum |
|---------------|------------------------------------|----------------|----------------|----------------|---------|
| Area under curve | 0.983                             | 0.993          | 0.991          | 0.999          | 0.999  |
| Sensitivity    | 92.4                               | 94.3           | 96.3           | 98.6           | 99.5   |
| Specificity    | 98.8                               | 100            | 99.2           | 99.6           | 98.2   |
| Accuracy       | 95.7                               | 97.3           | 97.9           | 99.2           | 98.8   |
| Cut-off CL value | 11.8                               | 14.4           | 14.7           | 15.6           | 17.7   |

those of the present study. Huang et al. (2013) found early amyloid accumulation in the precuneus, frontal cortex, and posterior cingulate gyrus and later deposition in the parietal, occipital, and lateral temporal cortex. Other studies (Cho et al., 2016; Mattsson et al., 2015; Palmqvist et al., 2017; Villeneuve et al., 2015) have reported a similar order of amyloid positivity in cortical regions, with early deposition in the medial frontal cortex and precuneus and posterior cingulate cortex followed by accumulation in the lateral temporal cortex and parietal cortex. On the other hand, it has been reported that striatal deposition follows cortical deposition (Hanseeuw et al., 2018). The current cutoff CL value of 11.8 for amyloid positivity in the posterior cingulate gyrus and precuneus is in good agreement with the CL threshold of 12.2 associated with the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) moderate-to-frequent neuritic plaques in the comparative study between standard postmortem measures of AD neuropathology and antemortem 11C-PiB PET (La Joie et al., 2019).

This study has some limitations. First, our newly developed software is not fully automatic. The first step requires setting of the origin of the PET and MRI images around the anterior commissure to avoid inaccurate coregistration due to the large distance between the PET and MRI origins. Semi-automatic or automatic reorientation would be preferable. Second, the small number of young control subjects from the amyloid-negative GAAIN database comprising datasets for 18F-labeled tracers could cause false-positive or -negative findings in Z-score analysis. Although there were no significant differences in the detection performance of regional positivity between 18F-labeled tracers and 11C-PiB, a larger negative database may be necessary to increase the accuracy of Z-score analysis for 18F-labeled tracers. Third, a longitudinal study in the same individuals may be necessary for more accurate
comprehension of the spatial and temporal ordering of amyloid pathology in AD.

5 | CONCLUSIONS

We developed standalone quantitative software for amyloid PET. In addition to reliably calculating the global CL scale, this software can detect significant local amyloid accumulation in an individual patient by comparison with a negative database of young healthy controls. This software can be applied to the five currently available amyloid PET tracers.

ACKNOWLEDGMENTS

This study was based on the GAAIN datasets. We are grateful to the project participants and the researchers who collected these datasets and made them freely accessible. We would also like to thank Dai Nippon Printing Co., Ltd. for their assistance with the development of this software. Dr. Cally Xiao of the University of Southern California and Professor William E Klunk of the University of Pittsburgh for allowing us to use the GAAIN datasets, and Professor John Ashburner of University College London for allowing us to incorporate SPM12 into this software.

CONFLICT OF INTEREST

No authors had conflicts of interest relevant to this study.

AUTHOR CONTRIBUTIONS

H. Matsuda and T. Yamao developed the study concept and contributed to the study design. H. Matsuda performed the data analysis and interpretation. All authors provide revisions and approved the final version of the paper for submission.

PEER REVIEW

The peer review process for this article is available at https://publons.com/publon/10.1002/brb3.2499.

ORCID

Hiroshi Matsuda https://orcid.org/0000-0002-6297-9897

REFERENCES

Amadoru, S., Doré, V., McLean, C. A., Hinton, F., Shepherd, C. E., Halliday, G. M., Leyton, C. E., Yates, P. A., Hodges, J. R., Masters, C. L., Villemagne, V. L., & Rowe, C. C. (2020). Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease. Alzheimer’s Research & Therapy, 12(1), 22. https://doi.org/10.1186/s13195-020-00587-5

Ashburner, J., & Friston, K. J. (2005). Unified segmentation. Neuroimage, 26(3), 839–851. https://doi.org/10.1016/j.neuroimage.2005.02.018

Battle, M. R., Pillay, L. C., Lowe, V. J., Knopman, D., Kemp, B., Rowe, C. C., Doré, V., Villemagne, V. L., & Buckley, C. J. (2018). Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods. EJNMMI Research, 8(1), 107. https://doi.org/10.1186/s13550-018-0456-7

Cho, H., Choi, J. Y., Hwang, M. S., Kim, Y. J., Lee, H. M., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2016). In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Annals of Neurology, 80(2), 247–258. https://doi.org/10.1002/ana.24711

Colli, L. E., Konijnenberg, E., Reimand, J., Kate, M. T., Braber, A. D., Lopes Alves, I., Zwan, M., Yaqub, M., van Assema, D., Wink, A. M., Lammertsma, A. A., Scheltens, P., Visser, P. J., Barkhof, F., & van Berckel, B. (2019). Assessing amyloid pathology in cognitively normal subjects using 18F-Flutemetamol PET: Comparing visual reads and quantitative methods. Journal of Nuclear Medicine, 60(4), 541–547. https://doi.org/10.2967/jnumed.118.211532

Hanseuuw, B. J., Betensky, R. A., Mormino, E. C., Schultz, A. P., Sepulcre, J., Becker, J. A., Jacobs, H., Buckley, R. F., LaPoint, M. R., Vannini, P., Donovan, N. J., Chhatwal, J. P., Marshall, G. A., Papp, K. V., Amariglio, R. E., Rentz, D. M., Sperring, R. A., Johnson, K. A., Alzheimer’s Disease Neuroimaging Initiative, & Harvard Aging Brain Study (2018). PET staging of amyloidosis using striatum. Alzheimer’s & Dementia, 14(10), 1281–1292. https://doi.org/10.1016/j.jalz.2018.04.011

Hosokawa, C., Ishii, K., Kimura, Y., Hyodo, T., Hosono, M., Sakaguchi, K., Usami, K., Shimamoto, K., Yamazoe, Y., & Murakami, T. (2015). Performance of 11C-Pittsburgh compound B PET binding potential images in the detection of amyloid deposits on equivocal static images. Journal of Nuclear Medicine, 56(12), 1910–1915. https://doi.org/10.2967/jnumed.115.156414

Huang, K. L., Lin, K. J., Hsiao, I. T., Kuo, H. C., Hsu, W. C., Chuang, W. L., Kung, M. P., Wey, S. P., Hsieh, C. J., Wai, Y. Y., Yen, T. C., & Huang, C. C. (2013). Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer’s disease evaluated by [18F]AV-45 positron emission tomography in Chinese population. Plos One, 8(3), e58974. https://doi.org/10.1371/journal.pone.0058974

Klunk, W. E., Koeppen, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Sr Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., Rowe, C. C., Skovronsksy, D. M., & Mintun, M. A. (2015). The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer’s & Dementia, 11(1), 1–15.e154. https://doi.org/10.1016/j.jalz.2014.07.003

La Joie, R., Ayakta, N., Seeley, W. W., Borys, E., Boxer, A. L., DeCarli, C., Doré, V., Grinberg, L. T., Huang, E., Hwang, J. H., Ikonomovic, M. D., Jack, C., Jr, J. W., Jin, L. W., Klunk, W. E., Kofler, J., Lesman-Segev, O. H., Lockhart, S. N., ... Rabinovici, G. D. (2019). Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and post-mortem measures of Alzheimer’s disease neuropathology. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 15(2), 205–216. https://doi.org/10.1016/j.jalz.2018.09.001

Matsuda, H., Ito, K., Ishii, K., Shimosegawa, E., Okazawa, H., Mishina, M., Mizumura, S., Ishii, K., Okita, K., Shigemoto, Y., Kato, T., Takenaka, A., Kaida, H., Hanaoka, K., Matsunaga, K., Hatazawa, J., Ikawa, M., Tsujikawa, T., Morooka, M., ... Sato, N. (2021). Quantitative evaluation of 18F-Flutemetamol PET in patients with cognitive impairment and suspected Alzheimer’s disease: A multicenter study. Frontiers in Neurology, 11, 578753. https://doi.org/10.3389/fneur.2020.578753

Mattsson, N., Insel, P. S., Donohue, M., Landau, S., Jagust, W. J., Shaw, L. M., Trojanowski, J. Q., Zetterberg, H., Blennow, K., Weiner, M. W., & Alzheimer’s Disease Neuroimaging Initiative (2015). Independent information from cerebrospinal fluid amyloid-β and flurbiprofen imaging in Alzheimer’s disease. Brain, 138(PT 3), 772–783. https://doi.org/10.1093/brain/awu367

Navitsky, M., Joshi, A. D., Kennedy, I., Klink, W. E., Rowe, C. C., Wong, D. F., Pontecorvo, M. J., Mintun, M. A., & Devous, M. D. (2018). Standardization of amyloid quantitation with flurbiprofen standardized uptake value ratios to the Centiloid scale. Alzheimer’s & Dementia, 14(12), 1565–1571. https://doi.org/10.1016/j.jalz.2018.06.1353

Palmqvist, S., Schöll, M., Strandberg, O., Mattsson, N., Stomrud, E., Zetterberg, H., Blennow, K., Landau, S., Jagust, W., & Hansson, O. (2017). Earliest accumulation of β-amyloid occurs within the default-mode network.
and concurrently affects brain connectivity. Nature Communications, 8(1), 1214. https://doi.org/10.1038/s41467-017-01150-x

Rowe, C. C., Jones, G., Doré, V., Pejoska, S., Margison, L., Mulligan, R. S., Chan, J. G., Young, K., & Villemagne, V. L. (2016). Standardized expression of 18F-NAV4694 and 11C-PiB β-amyloid PET results with the Centiloid scale. Journal of Nuclear Medicine, 57(8), 1233–1237. https://doi.org/10.2967/jnumed.115.171595

Rowe, C. C., Doré, V., Jones, G., Baxendale, D., Mulligan, R. S., Bullich, S., Stephens, A. W., De Santi, S., Masters, C. L., Dinkelborg, L., & Villemagne, V. L. (2017). 18F-Florbetaben PET beta-amyloid binding expressed in Centiloids. European Journal of Nuclear Medicine and Molecular Imaging, 44(12), 2053–2059. https://doi.org/10.1007/s00259-017-3749-6

Villeneuve, S., Rabinovici, G. D., Cohn-Sheehy, B. I., Madison, C., Ayakta, N., Ghosh, P. M., La Joie, R., Arthur-Bentil, S. K., Vogel, J. W., Marks, S. M., Lehmann, M., Rosen, H. J., Reed, B., Olichney, J., Boxer, A. L., Miller, B. L., Borys, E., Jin, L. W., Huang, E. J., … Jagust, W. (2015). Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: Statistical and pathological evaluation. Brain, 138(Pt 7), 2020–2033. https://doi.org/10.1093/brain/awv112

How to cite this article: Matsuda, H., & Yamao, T. (2022). Software development for quantitative analysis of brain amyloid PET. Brain and Behavior, 12, e2499. https://doi.org/10.1002/brb3.2499